Navigation Links
Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Date:4/27/2009

d clinical development positions for Novartis Pharma. Dr. Scaife began his career as the Regulatory and Medical Affairs Manager at Johnson & Johnson Medical Ltd., UK.

Dr. Scaife received a Ph.D. in Toxicology from Leicester School of Pharmacy, United Kingdom and a B.S. degree in Pharmacology from the University of Bath, United Kingdom.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the enrollment, timing and completion of clinical trials of Contrave, and the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
2. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
8. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
9. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
10. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
11. United Therapeutics to Announce 2009 First Quarter Financial Results Before Market Open on Friday, May 1, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... About Bioactive Material Bioactive ... are increasingly becoming popular due to their ability ... having a negative impact on the human health. ... tissue repair materials in surgical procedures. Bioactive materials ... glass-ceramics, and composites. The major end-users of bioactive ...
(Date:9/23/2014)... 23, 2014 Kamal Rashid , ... Education and Training Center (BETC) and research professor of ... BioTalk 2014 , an international two-day event focused on ... by Global Summits, the event will bring together leaders ... cells to develop and produce human therapeutics. “The growth ...
(Date:9/23/2014)... 2014 This is a professional ... the Phenolic Resin industry in Global and China.The ... including definitions, applications and industry chain structure. Global ... provided with a focus on history, developments, trends ... between the international and Chinese situation is also ...
(Date:9/23/2014)... Erlab , the expert in ... and Burdinola, supplier of laboratory furniture solutions, announce a ... hood. , By integrating Erlab’s GreenFumeHood ... now offer an innovative solution utilizing the patented technology ... best-in-class detection technology, and communication for security and monitoring ...
Breaking Biology Technology:Global Bioactive Material Market 2014-2018 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 3Phenolic Resin Industry (International, China) Development Policy and Plan Now Available at ReportsnReports.com 2Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2
... N.J., May 9 Barr Pharmaceuticals,Inc. (NYSE: ... Laboratories,Inc., has received final approval from the U.S. ... Drug Application (ANDA) to,manufacture and market a generic ... contraceptive product manufactured and marketed,by Bayer Schering Pharma, ...
... May 9 Genaera,Corporation (Nasdaq: GENR ) today announced ... net loss for the quarter ended March 31,2008 was $4.3 ... a net loss of $4.2 million, or $(0.24) per basic ... Genaera,s research and development expenses for the quarter ended March,31, ...
... 9 Schering-Plough,Corporation (NYSE: SGP ) will hold ... Memphis, Tenn. At 8 a.m. (CDT) (9 a.m. EDT) ... be available to all interested,parties via the corporate Web ... Fred Hassan, Chairman and CEO, will report to,shareholders on ...
Cached Biology Technology:Barr Announces Approval of Generic Yasmin(R) 2Barr Announces Approval of Generic Yasmin(R) 3Genaera Corporation Announces First Quarter Financial Results 2Genaera Corporation Announces First Quarter Financial Results 3Genaera Corporation Announces First Quarter Financial Results 4
(Date:9/23/2014)... the effects of temperature on insects to predict how ... a Dartmouth study shows for the first time that ... ultimately limits how fast they grow. , "In other ... overall environmental conditions that shape the growth, survival and ... Lauren Culler , an Arctic postdoctoral researcher at Dartmouth. ...
(Date:9/23/2014)... scientists has identified a gene mutation that causes ... the bone marrow fails to produce normal amounts ... three generations had blood disorders, the researchers discovered ... chromosomal structures with crucial roles in normal cell ... suggest future molecular-based treatments that bypass the gene ...
(Date:9/23/2014)... 23, 2014 Research and Markets  has ... Forecast and Opportunities, 2019" report to their offering. ... for enhancing security and protection in private as well ... The country,s government is focusing on using biometric systems ... other national IDs that are of crucial importance to ...
Breaking Biology News(10 mins):Insects' fear limits boost from climate change, Dartmouth study shows 2Gene mutation discovered in blood disorder 2India Biometrics Market Forecast and Opportunities, 2019 2India Biometrics Market Forecast and Opportunities, 2019 3
... can be swallowed like a pill, injected through a ... to screen for, detect, and potentially treat, cancer and ... size in early development stages. They will also ... researchers at McMaster University will be escalating efforts to ...
... some teenagers taking common anti-depressants may become more aggressive ... the October Behavioral Neuroscience, which is published by the ... of Texas at Austin found that juvenile hamsters given ... the United States as Prozac, became more aggressive on ...
... not be necessary in the event of a large-scale ... a study led by researchers at Fred Hutchinson Cancer ... of Infectious Diseases. , Instead, the current U.S. government ... vaccination of hospital workers and close contacts would be ...
Cached Biology News:Nano-devices hold promise for early-stage cancer detection 2Nano-devices hold promise for early-stage cancer detection 3Adolescent but not adult hamsters are more aggressive on low dose of fluoxetine 2Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 2Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 3Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 4Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 5
... BR4i refrigerated multifunction centrifuges are equally capable of ... low sound level with a large range of ... rotor exchange system without tools ensures that the ... Instant rotor exchange (5 sec.) ...
... ,Each upright model provides fast pull-down, rapid ... for refrigerated blood. The BBR25 and BBR55 ... complete blood storage monitoring. Models BBR6, BBR11, ... HemaPro 101 alarm/monitor. All of these models ...
Sterile, individually wrapped, 4mm Cuvettes...
... form of Tobacco Etch Virus (TEV) protease ... significantly more stable than native TEV protease, ... recognizes a seven amino acid (Glu-Asn-Leu-Tyr-Phe-Gln-Gly, cleaving ... for removing affinity tags from fusion proteins ...
Biology Products: